Limited data exist on UTI burden among HF patients on SGLT2 inhibitors in low-resource settings.<h4>Objective</h4>This study aimed to determine the prevalence of UTIs, associated factors, and antimicrobial susceptibility patterns of uropathogens in HF patients receiving SGLT2 inhibitors at the Jakaya Kikwete Cardiac Institute (JKCI) in Tanzania.<h4>Methods</h4>A hospital-based cross-sectional study was conducted from March to June 2024 among HF patients aged ≥18 years on SGLT2 inhibitors. This evidence concerns the gene SLC5A2 and bacterial urinary tract infection.